ABSTRACT A method was developed for the synthesis of high-specific-activity 21-diazo-21[6,7-3Hdeoxycorticosterone, an analog of corticosterone. This analog was used as a photoaffinity label of a high affinity steroid-binding protein, human corticosteroid-binding globulin. Based on direct binding studies and crosscompetition experiments, this diazo derivative exhibited the requisite affinity (within a factor of 1.5 times that of corticosterone) and site specificity to qualify as an affinity labeling ligand. Purification and definition of the properties of the corticosteroid receptors have been frustrated by their low abundance in cytoplasm and irreversible loss of binding activity during isolation (1-4). In principle, these problems could be circumvented by site-specific covalent labeling of the receptor (5, 6). In a previous study, 21-diazo derivatives of corticosteroids exhibited reasonable affinities for intracellular receptors and functional activity in a toad bladder assay (5). In addition, covalent labeling of plasma proteins was obtained with 9a-bromo-21-diazo-21-[1,2-3H]deoxycorticosterone. The utility of this compound was limited, however, by the low specific activity (25 Ci/mol). We now report on the preparation of high-specific-activity 21-diazo-21- [6,7-3H] (5) with the following solvent systems: system A, benzene-ethyl acetate (1:2 vol/vol); system B, benzene-ethanol (6:1 vol/vol); system C, chloroform-ethyl acetate (1:3 vol/vol). Melting points, microanalyses, and. UV spectroscopy were performed as described (5). Catalytic tritiation was performed with the assistance of Dr. Chin-Tzu Peng and Mr. Ray Aune at the Lawrence Radiation Laboratory (Berkeley, Calif.). The reaction sequence used to prepare 21-diazo-21-[6,7-3H]deoxycorticosterone (compound V) is shown in Fig. 1 . Compound II was obtained by treatment of compound I (2.0 g) with chloranil (6.5 g) in t-butanol (120 ml). The filtered mixture was evaporated, taken up in ether, washed with dilute NaOH and water, and reevaporated. The residue was crystallized from aqueous methanol; mp 171-174°[lit. mp 155-177° (8)], Xmax 286 nm. Compound-III was prepared by reaction of compound II (0.9 g in 10 ml of dioxane + 1.5 ml of H20) with sodium hypobromite (prepared from 0.3 ml of Br2 and 0.5 g of NaOH in 8 ml of H20) at 00. The reaction mixture was diluted with dioxane (4 ml), stirred for 2.5 hr at 00, treated with NaHSO3 (50 mg) for 15 min, extracted with ether, and acidified with HCL. The precipitate was washed with H20 and crystallized from aqueous acetone (mp 270-275°, Xmax 286 nm) (Anal. calcd. for C20H2604: C, 72.70; H, 7.93. Found: C, 72.54; H, 7.83). Compound IV [mp 251-255°, Xmax 242 nm, (E 1.55 X 104)] was prepared from compound I as described (5). Compound V [mp 1750 (dec), Xmax 247 nm (E 2.3 X 104)], with a shoulder at 280 nm, was prepared from compound IV as described (5). Tritium-labeled compound IV (at C6-C7) was obtained by catalytic tritiation of compound III in benzene-tetrahydrofuran solvent using 10% palladium on charcoal and carrier-free tritium gas in a microhydrogenation apparatus using vacuum line techniques. Analysis of the product by UV spectroscopy indicated the absence of compound III and a 45% yield of compound IV. A 2:3 mixture of the crude 3H-labeled product and unlabeled compound IV was reacted with oxalyl chloride in benzene at 50, and lyophilized. The residue was dissolved in benzene and treated with ethereal diazomethane under cooling by dry ice/ acetone (9). After TLC twice in solvent systems A and B, purified tritiated compound V (21-diazo-21-[6,7-3H]deoxycorticosterone) was recovered (36% yield) with a specific activity of 7 Ci/mmol and a purity of 98% (by TLC in system C). Identity was also confirmed by (i) photolysis at 253.7 and 300 nm, which gave the same results with 3H product as with authentic compound V (Fig. 2) 
Preparation of 21-Diazo-21 [6,7-3H] deoxycorticosterone. Thin-layer chromatography (TLC) was done as described (5) with the following solvent systems: system A, benzene-ethyl acetate (1:2 vol/vol); system B, benzene-ethanol (6:1 vol/vol); system C, chloroform-ethyl acetate (1:3 vol/vol). Melting points, microanalyses, and. UV spectroscopy were performed as described (5) . Catalytic tritiation was performed with the assistance of Dr. Chin-Tzu Peng and Mr. Ray Aune at the Lawrence Radiation Laboratory (Berkeley, Calif.). The reaction sequence used to prepare 21-diazo-21-[6,7-3H]deoxycorticosterone (compound V) is shown in Fig. 1 . Compound II was obtained by treatment of compound I (2.0 g) with chloranil (6.5 g) in t-butanol (120 ml). The filtered mixture was evaporated, taken up in ether, washed with dilute NaOH and water, and reevaporated. The residue was crystallized from aqueous methanol; mp 171-174°[lit. mp 155-177° (8) ], Xmax 286 nm. Compound-III was prepared by reaction of compound II (0.9 g in 10 ml of dioxane + 1.5 ml of H20) with sodium hypobromite (prepared from 0.3 ml of Br2 and 0.5 g of NaOH in 8 ml of H20) at 00. The reaction mixture was diluted with dioxane (4 ml), stirred for 2.5 hr at 00, treated with NaHSO3 (50 mg) for 15 min, extracted with ether, and acidified with HCL. The precipitate was washed with H20 and crystallized from aqueous acetone (mp 270-275°, Xmax 286 nm) (Anal. calcd. for C20H2604: C, 72.70; H, 7.93. Found: C, 72.54; H, 7.83). Compound IV [mp 251-255°, Xmax 242 nm, (E 1.55 X 104)] was prepared from compound I as described (5) . Compound V [mp 1750 (dec), Xmax 247 nm (E 2.3 X 104)], with a shoulder at 280 nm, was prepared from compound IV as described (5) . Tritium-labeled compound IV (at C6-C7) was obtained by catalytic tritiation of compound III in benzene-tetrahydrofuran solvent using 10% palladium on charcoal and carrier-free tritium gas in a microhydrogenation apparatus using vacuum line techniques. Analysis of the product by UV spectroscopy indicated the absence of compound III and a 45% yield of compound IV. A 2:3 mixture of the crude 3H-labeled product and unlabeled compound IV was reacted with oxalyl chloride in benzene at 50, and lyophilized. The residue was dissolved in benzene and treated with ethereal diazomethane under cooling by dry ice/ acetone (9) . After TLC twice in solvent systems A and B, purified tritiated compound V (21-diazo-21-[6,7-3H]deoxycorticosterone) was recovered (36% yield) with a specific activity of 7 Ci/mmol and a purity of 98% (by TLC in system C). Identity was also confirmed by (i) photolysis at 253.7 and 300 nm, which gave the same results with 3H product as with authentic compound V (Fig. 2) 11 ,-hydroxy-3-oxo-androst-4,6-diene-17fl-carboxylic acid; compound IV, 1lf-hydroxy-3-oxo-androst-4-ene-17,B-carboxylic acid; compound V, 21-diazo-11#-hydroxypregn-4-ene-3,20-dione (21-diazo-21-deoxycorticosterone); compound VI, methyl-11,i-hydroxy-3-oxopregn-4-ene-21-oate; compound VII, 21-chloro-11jl-hydroxypregn-4-ene-3,20-dione. Tritiation is denoted by asterisks (*).
[3H]cortisol (2.88 Ag/ml) to enhance stability (11 (Fig. 3) . This is a consequence of dissociation from CBG during stacking. In contrast, three peaks (RF 0.25, 0.5, and 0.85 with respect to the dye front) were apparent after 30, 60, and 90 sec of irradiation, with a maximal yield after 60 sec. Under these electrophoretic conditions, CBG has an RF of about 0.5 (16) .
To test the specificity of labeling, we incubated the CBG preparation with 2 X 10-7 M 21-diazo-21-[6,7-3H]deoxycorticosterone with or without 100-fold excess of unlabeled corticosterone, cortisol, or aldosterone prior to UV irradiation. The results confirm the presence of three peaks of 3H activity (Fig.  4A) . Only the middle peak was eliminated by glucocorticoids that bind to CBG: corticosterone (Fig. 4B) and cortisol (Fig. 4D ) (15) . In contrast, aldosterone (Fig. 4C ), a steroid with very little affinity for CBG, had no effect on the labeling pattern (15) . These results show that the binding of the 3H-labeled diazo compound to CBG had the requisite specificity. Peaks (Fig. 4H) . This thermostability experiment was also prompted by the possibility that peak 2 contained albumin rather than CBG because albumin is a scavenger in photolytic reactions and also has an Rf of about 0.5 under these conditions (17) . Inasmuch as CBG is inactivated at 600 and albumin is not, the loss of binding in Fig. 4H confirms that peak 2 contains CBG.
The stability of the photoproduct was explored with studies on exchange-resistance. CBG (Table 1) , whereas the bound 3H-labeled diazo derivative was progressively less exchangeable in proportion to the duration of irradiation.
Further evidence that the 3H-labeled diazo derivative is covalently bound to CBG was obtained in solvent extraction studies. Duplicate samples of glycerol-Tris buffer with or without CBG were incubated with 2 X 10-7 M [3H]corticosterone or 21-diazo-21-[6,7-3H]deoxycorticosterone and irradiated. Free steroid was removed with charcoal-dextran, leaving 2.8 X 10-12 mol bound per ,ug of protein. Aliquots were then extracted with either methylene dichloride (once) or ethyl acetate (twice) as described (18) . The solvent: H20 partition coefficients computed from extractions of protein-free solutions were 0.18 for both steroids in CH2Cl2, and 0.24 for corticosterone and 0.36 for the diazo derivative in CH3COOC2H5. Methylene dichloride extracted 83% of the [3H]corticosterone and only 6% of the 3H-labeled diazo derivative. Similarly, ethyl acetate extracted 90% (85 + 5) of the [3H]corticosterone and only 21% (20 + 1) of the 3H-labeled diazo derivative. These results imply covalent binding of the diazo derivative to CBG.
To explore the issue of site-specific labeling, we exploited two techniques: (i) the effects of a scavenger on photoaffinity la- beling of the CBG, and (ii) fluorescence quenching analysis. Photolysis of the diazoketones produces the corresponding ketene capable of acylating amines (19) . Accordingly, Tris-HCl was substituted for the P04 in the buffer to provide an excess of amines as reactants for photoactivated 3H-labeled diazo derivative and thereby minimize secondary labeling of the CBG. Aliquots of the CBG preparation were incubated with 21-diazo-21-[6,7-3H]deoxycorticosterone (2 X 10-7 M) in glycerol-PO4 or glycerol-Tris buffer. The preparations were irradiated and the products analyzed by electrophoresis. Photolysis in P04 buffer produced the usual labeling pattern (Fig.  5A ). In the presence of Tris, however, the major nonspecific component, in peak 3, was essentially eliminated, whereas labeling of peak 2 material (CBG) was augmented to some extent (Fig. 5B) . These results imply that covalent attachment ensued in the bound state rather than from derivatives with access to the solvent.
A test for assessing site-specific steroid occupancy is the fluorescence quenching technique (13) . Steroid binding in close proximity to a fluorescence donor (e.g., tryptophan in CBG) results in quenching if the absorption spectrum of the steroid acceptor overlaps extensively with the emission spectrum of the donor. The efficiency of fluorescence quenching depends on the distance between donor and acceptor by the relationship: E = R06/(R6 + R16) 06] where E denotes the efficiency of quenching, R0 the distance in A for equal probability of radiationless energy transfer, and R the distance in A between donor and acceptor. In previous studies with progesterone-binding globulin, both deoxycorticosterone and progesterone, which contain M4-3 keto functions (sites of energy absorption), were efficient quenchers (13) .
Because the CBG preparation used in the current studies contained cortisol, it was necessary to replace this steroid with one that would bind to the site but had minimal-quenching activity. Stroupe et al. (13) introduced the use of 5fB-pregnane-3,20-dione (pregnanedione) as a "see-through" steroid since it lacks the A4-3 keto structure. For these studies we have substituted pregnanediol. The first set of experiments consisted of three steps. (i) Pregnanediol (10-4 M) was added to CBG (5 Asg of protein per ml) or the diluent in glycerol-Tris buffer. (it) Corticosterone or the 21-diazo derivative or the diluents were added in successive increments to pairs of cuvettes. Triplicate readings were begun 5 min after each addition. Fluorescence quenching reached the same limiting value (56% of control) at 10-6 to 4 X 10-6 M of either steroid, implying that both occupied the same site (Fig. 6A) . (iii) Samples in all cuvettes were then irradiated and reassayed. Irradiation had no effect on fluorescence quenching with either steroid, indicating unchanged orientations of the CBG fluorophore and steroid chromophores.
Biochemistry: Marver et al. To ensure that photolysis resulted in irreversible binding of the 21-diazo derivative to the primary site, the reversal of quenching by exchange with pregnanediol was assessed. CBG preparations (5 ,ug of protein per ml) or the diluent in glycerol-Tris buffer were incubated in pairs with corticosterone (2 X 10-7 M) or 21-diazo derivative (2 X 10-7 M) or pregnanediol (10-4 M), for 15 min at 250. One of each pair of cuvettes was irradiated and the fluorescence yield determined. Corticosterone and the 21-diazo derivative quenched fluorescence to the same extent with and without irradiation (points at the origin) (Fig. 6B) . Additions of pregnanediol reversed corticosterone quenching regardless of irradiation and that of the nonirradiated 21-diazo derivative. No reversal of quenching was obtained in the irradiated complexes of 21-diazo derivative (Fig. 6B) .
The results in Fig. 6 enable an estimation of R, the distance between donor and acceptor (Eq. 1). To do so, Ro was computed from Forster's equation (20) Ro = 9.79 X 103(K2n-4QJ)1/6 [2] The following values were used: K2 (dipole-dipole orientation factor) = 4 (13); n (refractive index of medium at site) = 1.5 (13) (Fig. 6 ). In summary, photoactivation of 21-diazo derivative:CBG results in covalent attachment to the primary binding site. This technique hopefully should contribute to purification and characterization of intracellular glucocorticoid receptors as well.
